Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States

University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States

Sarah Cannon - Colorado Blood Cancer Institute, Denver, Colorado, United States

University of Chicago, Chicago, Illinois, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States

Weill Medical College of Cornell University, New York, New York, United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Sarah Cannon - HCA Research Institute, Nashville, Tennessee, United States

Sarah Cannon - St. David's South Austin Medical Center, Austin, Texas, United States

MD Anderson Cancer Center, Houston, Texas, United States

Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio, Texas, United States

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

CHU de Nantes - Hôtel-Dieu, Nantes, France

Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie, Paris, France

Hôpital Robert Debré - Service d'hémato-immunologie, Paris, France

Hôpital Lyon Sud, Pierre-Bénite, France

CHU Rennes - Hopital Pontchaillou, Rennes, France